Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of September. Event:  Citi 15 th Annual Biopharma Conference Date:  September 9, 2020 Format: 1:1
Toggle Summary Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
ANN ARBOR, Mich., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will present a pooled analysis from four Phase 3 clinical trials of NEXLETOL ® (bempedoic acid) tablets as well as long-term safety and efficacy data from the CLEAR Harmony open-label extension study
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 19, 2020, the Compensation Committee of Esperion’s Board of Directors granted 25,566 restricted stock units (RSUs) to 28 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
Toggle Summary Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
– Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue – – Strong Capital Position with over $300 Million in Cash – – Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage –
Toggle Summary Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will host a webcast and conference call at